NCT03673423

Brief Summary

Assess the degree of vascular involvement is crucial in the diagnostic and therapeutic work-up of pancreatic cancer. NCCN resectability classification is used to stratify patients (in resectable, borderline resectable and non resectable) and is based on contrast-enhanced CT scan images. Unfortunately evaluation of imaging tests may rely on some degree of subjective interpretation by observers implying a fundamental variation in patient's treatments and an irreproducibility of different center study results. This is a multicenter diagnostic study on interobserver agreement on the resectability of pancreatic cancer based upon NCCN criteria. The primary aim of the study will be the assessment of interobserver variability to define vascular invasion and resectability status on CT scans (according to the last version of the NCCN Classification). One hundred and thirty eight consecutive patients, able to produce an informed consent, from 18 years of age, with a non-metastatic pancreatic adenocarcinoma assessed by a contrast-enhanced high-quality CT scan will be enrolled. 69 CT scan studies provided by the centers involved (High volume for pancreatic surgery) will be randomly selected from a pool of 138 of the patients that meet the inclusion criteria. Each study will be independently reviewed by a senior radiologist and a senior surgeon of each center, blinded to patient's clinical history and CT scan report, using NCCN definition of respectability status. A CFR will be filled during the review and send to the study coordinator. The data will be than centrally analyzed to asses interobserver agreement The enrolment phase will last 6 months and the whole study will last 8 months.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
138

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Sep 2018

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

September 5, 2018

Completed
7 days until next milestone

First Submitted

Initial submission to the registry

September 12, 2018

Completed
5 days until next milestone

First Posted

Study publicly available on registry

September 17, 2018

Completed
6 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 5, 2019

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

May 5, 2019

Completed
Last Updated

December 13, 2018

Status Verified

December 1, 2018

Enrollment Period

6 months

First QC Date

September 12, 2018

Last Update Submit

December 11, 2018

Conditions

Keywords

Resectability StatusNCCN criteria

Outcome Measures

Primary Outcomes (1)

  • Assessment of interobserver variability to define vascular invasion and resectability status on CT scans

    The primary aim of the study will be the assessment of interobserver variability to define vascular invasion and resectability status on CT scans (according to the last version of the NCCN Classification).

    Eight months

Secondary Outcomes (1)

  • Identification of disagreement causes and proposal of a new classification system

    One year

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

138 Consecutive patients, able to produce an informed consent, from 18 years of age, with a non-metastatic pancreatic adenocarcinoma assessed by a contrast-enhanced high-quality CT scan.

You may qualify if:

  • Age \> 18 years
  • Non-metastatic pancreatic adenocarcinoma
  • Availability of contrast enhanced CT scan with adequate quality. Section thickness must be \<3 mm, according to NCCN recommendations
  • Pathological confirmation of pancreatic adenocarcinoma by cytology/histology is not required at the time of enrolment, but it is needed before including the CT scan in the pool of exams to be evaluated.
  • Signed informed consent

You may not qualify if:

  • Evidence of metastatic disease
  • Inadequate quality CT scan (non-respecting the NCCN recommendations)
  • Absence of cytology/histology confirmation
  • Refusal to participate in the study

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Ospedale San Raffaele

Milan, 20132, Italy

RECRUITING

Study Officials

  • Gianpaolo Balzano, MD

    Ospedale San Raffaele

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Fabio Giannone, MD

CONTACT

Study Design

Study Type
observational
Observational Model
OTHER
Time Perspective
CROSS SECTIONAL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

September 12, 2018

First Posted

September 17, 2018

Study Start

September 5, 2018

Primary Completion

March 5, 2019

Study Completion

May 5, 2019

Last Updated

December 13, 2018

Record last verified: 2018-12

Data Sharing

IPD Sharing
Will not share

Locations